Compare GSK plc (GSK) vs 3M Company (MMM) Price & Performance

GSK trades at $52.16, down 1.51% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates, and announced a $2.52 billion cost-saving plan to accelerate drug development. Revenue growth remains steady, with 2025 revenue at $32.67 billion and net income of $5.72 billion, though profit margins have fluctuated in recent years.

Outlook is positive with continued earnings beats and strategic investments, but risks include competitive pressures and regulatory uncertainties. Analyst sentiment is mixed with 31% buy ratings, 55% hold, and 14% sell, reflecting cautious optimism amid execution risks and market volatility.

3M (MMM) trades at $183.58, up 0.85% with strong technical momentum and bullish moving average signals. The company delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $2.40 exceeding expectations by 6.7%, and raised full-year guidance. Revenue trends show stabilization after 2023 challenges, with 2025 revenue of $24.95B and net income margin of 13.02%. Analyst sentiment is mixed with 48% buy ratings but the stock trades above the consensus price target of $173.

The outlook remains positive with operational improvements and innovation driving growth, particularly in Safety & Industrial and Transportation segments. Key risks include litigation liabilities, macroeconomic headwinds, and valuation concerns with elevated P/E of 32.5. The EBO partnership with Microsoft presents long-term data center growth opportunities, though current pricing may limit near-term upside potential.